INT25772

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1989
Last Reported 2008
Negated 1
Speculated 1
Reported most in Abstract
Documents 15
Total Number 16
Disease Relevance 3.80
Pain Relevance 7.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (HTR1B) cytoplasm (HTR1B) signal transducer activity (HTR1B)
Anatomy Link Frequency
neuronal 1
blood vessels 1
brain 1
HTR1B (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 26 100.00 Very High Very High Very High
fluoxetine 7 100.00 Very High Very High Very High
antidepressant 4 100.00 Very High Very High Very High
Triptan 39 99.76 Very High Very High Very High
antagonist 17 99.58 Very High Very High Very High
Migraine 86 99.44 Very High Very High Very High
Substantia nigra 3 99.32 Very High Very High Very High
Serotonin 25 98.84 Very High Very High Very High
Potency 4 98.44 Very High Very High Very High
Neurotransmitter 2 98.36 Very High Very High Very High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 8 99.90 Very High Very High Very High
Headache 75 99.44 Very High Very High Very High
Migraine Disorders 28 99.20 Very High Very High Very High
Nociception 2 98.52 Very High Very High Very High
Cluster Headache 2 97.84 Very High Very High Very High
Disease 3 97.08 Very High Very High Very High
Schizophrenia 2 93.00 High High
Pain 91 85.24 High High
Depression 4 83.40 Quite High
Hypotension 5 80.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, agents that modulate 5-HT1B, 5-HT1D, 5-HT1F and 5-HT2B receptors either have or may have clinical utility in the therapy of migraine headache.
Regulation (modulate) of 5-HT1B associated with migraine and headache
1) Confidence 0.60 Published 1998 Journal Prog Drug Res Section Abstract Doc Link 9949863 Disease Relevance 1.20 Pain Relevance 1.60
To evaluate this hypothesis, we measured the effects of the antidepressant fluoxetine on neuronal levels of 5-HT1B receptor mRNA, the putative serotonin terminal autoreceptor in rat brain, and on serotonin transporter mRNA, the direct site of fluoxetine binding.
Regulation (effects) of 5-HT1B in neuronal associated with antidepressant, serotonin and fluoxetine
2) Confidence 0.60 Published 1996 Journal Neuropsychopharmacology Section Abstract Doc Link 8914125 Disease Relevance 0.17 Pain Relevance 1.08
In radioligand-binding experiments, eugenosedin-B had significant binding affinities on alpha1, alpha2, beta1, 5-HT1B, and 5-HT2A receptors.
Regulation (affinities) of 5-HT1B
3) Confidence 0.44 Published 2008 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 18287883 Disease Relevance 0.35 Pain Relevance 0.28
In the present study, the role of the 5-HT1A and 5-HT1B receptors in migraine was evaluated.
Regulation (role) of 5-HT1B associated with migraine
4) Confidence 0.44 Published 2007 Journal J Neural Transm Section Abstract Doc Link 17417740 Disease Relevance 0.44 Pain Relevance 0.26
In vitro pharmacology experiments showed that the 5-hydroxytryptamine (5-HT) type 1B and 1D receptor agonists, eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan, induced vasoconstriction in the thoracic blood vessels from 38% to 57% of the patients. 5-carboxamidotryptamine (5-CT) and sumatriptan elicited a vasoconstriction that was antagonized by the 5-HT1B receptor antagonist SB224289, whereas the 5-HT1D receptor antagonist BRL115572 had no effect. 5-HT induced a contraction that was inhibited by the 5-HT2A receptor antagonist ketanserin. 5-HT2A, 5-HT1B, and 5-HT1D receptor mRNA levels were detected by real-time PCR in all blood vessels studied.
Regulation (detected) of 5-HT1B in blood vessels associated with sumatriptan, antagonist, agonist and increased venous pressure under development
5) Confidence 0.44 Published 2005 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 15821444 Disease Relevance 0.42 Pain Relevance 0.90
The 5-HT1B receptors act as terminal receptors and are involved in regulation of the release of various neurotransmitters, including 5-HT itself.
Regulation (involved) of 5-HT1B associated with neurotransmitter
6) Confidence 0.44 Published 2004 Journal Neurosci Biobehav Rev Section Abstract Doc Link 15527863 Disease Relevance 0.06 Pain Relevance 0.50
OBJECTIVE: To determine the cost-effectiveness of the 5-HT1B/1D agonists, or triptans, in the acute treatment of migraine.
Spec (determine) Regulation (cost-effectiveness) of 5-HT1B associated with migraine, triptan and agonist
7) Confidence 0.44 Published 2003 Journal J Manag Care Pharm Section Abstract Doc Link 14613361 Disease Relevance 0.17 Pain Relevance 0.40
In conclusion, our data suggest that the Cys-124 variant significantly affects the pharmacological properties of the h5-HT1B receptor.
Regulation (affects) of 5-HT1B
8) Confidence 0.44 Published 1999 Journal Pharmacogenetics Section Abstract Doc Link 10208648 Disease Relevance 0.35 Pain Relevance 0.36
In radioligand binding studies on rat brain membranes, BRL 43694 had little or no affinity for 5-HT1A, 5-HT1B, 5-HT2 or for many other binding sites.
Neg (little) Regulation (affinity) of 5-HT1B in brain
9) Confidence 0.44 Published 1989 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2540014 Disease Relevance 0 Pain Relevance 0.13
In the present experiments, we studied the effects of a new non-indole 5-HT1B/1D receptor agonist, alniditan, on systemic and carotid haemodynamics in anaesthetised pigs.
Regulation (effects) of 5-HT1B associated with agonist
10) Confidence 0.44 Published 1998 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9687003 Disease Relevance 0.17 Pain Relevance 0.19
Finally, this study reveals the antagonistic roles of 5-HT2A and 5-HT2B receptors in regulating the function of 5-HT1B/1D, a receptor involved in neuropsychiatric disorders and migraine pathogenesis.
Regulation (regulating) of 5-HT1B associated with migraine
11) Confidence 0.44 Published 1998 Journal J. Biol. Chem. Section Abstract Doc Link 9651340 Disease Relevance 0.10 Pain Relevance 0.10
The differential regulation of 5-HT1A and 5-HT1B/D agonist responses by GDP suggests that different G-protein subtypes are involved upon 5-HT1A receptor activation by 5-HT1A and 5-HT1B/D agonists.
Regulation (regulation) of 5-HT1B associated with agonist
12) Confidence 0.44 Published 1998 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 9650800 Disease Relevance 0 Pain Relevance 0.44
Presynaptic 5-HT 1B/D receptors take part in the control of the release not only of 5-HT itself, but also of other neurotransmitters-for example, acetylcholine, glutamate, dopamine, noradrenaline and gamma-aminobutyric acid.
Regulation (control) of 5-HT 1B associated with dopamine, glutamate, neurotransmitter and noradrenaline
13) Confidence 0.44 Published 1997 Journal Gen. Pharmacol. Section Abstract Doc Link 9378233 Disease Relevance 0.06 Pain Relevance 0.32
These data suggest that a single amino acid difference at position 355 is responsible for the pharmacological differences between the rat and human 5-HT1B receptors.
Regulation (responsible) of 5-HT1B
14) Confidence 0.44 Published 1993 Journal J. Neurochem. Section Abstract Doc Link 8417162 Disease Relevance 0 Pain Relevance 0.09
We took advantage of a serotonergic cell line to elucidate cross-talks between 5-HT receptors and to demonstrate the involvement of two 5-HT2 receptor subtypes in the regulation of 5-HT1B/1D function.
Regulation (regulation) of 5-HT1B
15) Confidence 0.26 Published 1998 Journal J. Biol. Chem. Section Abstract Doc Link 9651340 Disease Relevance 0 Pain Relevance 0
As regards its action, it has been postulated that almotriptan, like other triptans, induces both vasoconstriction, by acting on the 5-HT1B receptor subtype, and inhibition of nociceptive transmission, via 5-HT1D receptor interaction (Bou et al 2001; Hoskin et al 2004).
Regulation (acting) of 5-HT1B associated with nociception, triptan and increased venous pressure under development
16) Confidence 0.26 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656322 Disease Relevance 0.31 Pain Relevance 0.52

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox